Fusion Antibodies (LSE:FAB) Debt-to-Equity : 0.03 (As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies Debt-to-Equity?

Fusion Antibodies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was £0.02 Mil. Fusion Antibodies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was £0.03 Mil. Fusion Antibodies's Total Stockholders Equity for the quarter that ended in Sep. 2023 was £1.45 Mil. Fusion Antibodies's debt to equity for the quarter that ended in Sep. 2023 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Fusion Antibodies's Debt-to-Equity or its related term are showing as below:

LSE:FAB' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.04 Max: 0.13
Current: 0.03

During the past 9 years, the highest Debt-to-Equity Ratio of Fusion Antibodies was 0.13. The lowest was 0.01. And the median was 0.04.

LSE:FAB's Debt-to-Equity is ranked better than
81.03% of 1070 companies
in the Biotechnology industry
Industry Median: 0.145 vs LSE:FAB: 0.03

Fusion Antibodies Debt-to-Equity Historical Data

The historical data trend for Fusion Antibodies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies Debt-to-Equity Chart

Fusion Antibodies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

0.03

0.08

0.05

0.02

0.07

Fusion Antibodies Semi-Annual Data
	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial											0.04	0.02	0.13	0.07	0.03

Competitive Comparison of Fusion Antibodies's Debt-to-Equity

For the Biotechnology subindustry, Fusion Antibodies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fusion Antibodies's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Antibodies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Fusion Antibodies's Debt-to-Equity falls into.

Fusion Antibodies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Fusion Antibodies's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.035	+	0.04)	/	1.123
	=	0.07

Fusion Antibodies's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.017	+	0.03)	/	1.454
	=	0.03

Fusion Antibodies (LSE:FAB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Fusion Antibodies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusion Antibodies (LSE:FAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL

Website

https://www.fusionantibodies.com

Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies (LSE:FAB) Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor • 10-21-2022